Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Hetero 2-mer - A1B 

Biological assembly 1 assigned by authors and generated by PISA (software)

Biological Assembly Evidence: gel filtration

Macromolecule Content

• Total Structure Weight: 53.50 kDa 
• Atom Count: 3926 
• Residue Count: 431 
• Unique protein chains: 2

5W24

Crystal Structure of 5C4 Fab

• DOI: 10.2210/pdb5W24/pdb

• Classification: IMMUNE SYSTEM
• Organism(s): Mus musculus
• Expression System: Homo sapiens
• Mutation(s): No 


• Deposited: 2017-06-05 Released: 2017-12-06 
• Deposition Author(s): Battles, M.B., McLellan, J.S., Taher, N.M.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 1.50 Å
• R-Value Free: 0.203 
• R-Value Work: 0.170 
• R-Value Observed: 0.171 

Literature

Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein.

Tian, D., Battles, M.B., Moin, S.M., Chen, M., Modjarrad, K., Kumar, A., Kanekiyo, M., Graepel, K.W., Taher, N.M., Hotard, A.L., Moore, M.L., Zhao, M., Zheng, Z.Z., Xia, N.S., McLellan, J.S., Graham, B.S.

(2017) Nat Commun 8: 1877-1877

• PubMed: 29187732 
• DOI: 10.1038/s41467-017-01858-w
• Structures With Same Primary Citation


• PubMed Abstract: 
  

A licensed vaccine for respiratory syncytial virus (RSV) is unavailable, and passive prophylaxis with the antibody palivizumab is restricted to high-risk infants. Recently isolated antibodies 5C4 and D25 are substantially more potent than palivizumab, and a derivative of D25 is in clinical trials. Here we show that unlike D25, 5C4 preferentially neutralizes subtype A viruses. The crystal structure of 5C4 bound to the RSV fusion (F) protein reveals that the overall binding mode of 5C4 is similar to that of D25, but their angles of approach are substantially different. Mutagenesis and virological studies demonstrate that RSV F residue 201 is largely responsible for the subtype specificity of 5C4. These results improve our understanding of subtype-specific immunity and the neutralization breadth requirements of next-generation antibodies, and thereby contribute to the design of broadly protective RSV vaccines.

---

Related Citations: 

• Structure of 5C4 Fab
  Battles, M.B., McLellan, J.S., Taher, N.M.
  () To be published --: --

---

Organizational Affiliation: 

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA. [e-mail].

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
5C4 Fab Light Chain	L	241	Mus musculus	Mutation(s): 0

Entity ID: 2
Molecule	Chains	Sequence Length	Organism	Details
5C4 Fab Heavy Chain	H	249	Mus musculus	Mutation(s): 0

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
BU3	H	(R,R)-2,3-BUTANEDIOL C4 H10 O2 OWBTYPJTUOEWEK-QWWZWVQMSA-N

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 1.50 Å
• R-Value Free: 0.203 
• R-Value Work: 0.170 
• R-Value Observed: 0.171 
• Space Group: C 1 2 1
• Diffraction Data DOI: 10.15785/SBGRID/537 SBGrid

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 116.96	α = 90
b = 63.01	β = 98.6
c = 56.54	γ = 90

Software Package:

Software Name	Purpose
PHENIX	refinement
Aimless	data scaling
PDB_EXTRACT	data extraction
Aimless	data reduction
PHASER	phasing

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2017-06-05 
• Released Date: 2017-12-06 
Deposition Author(s): Battles, M.B., McLellan, J.S., Taher, N.M.

Revision History 

• Version 1.0: 2017-12-06
  Type: Initial release
  
• Version 1.1: 2017-12-13
  Changes: Database references